01—Abstract
Summary
Summary of the 8-K filed December 20, 2024. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals announced a significant milestone with the U.S. Food and Drug Administration's approval of ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) on December 19, 2024.
This new therapy targets cystic fibrosis (CF) in patients aged 6 and older who possess at least one F508del mutation or another responsive mutation in the CFTR gene. The approval represents a key advancement in Vertex's CF franchise and offers a new treatment option for a broad segment of the CF patient population. The company has also set the wholesale acquisition cost (WAC) for ALYFTREK in the United States at $370,269a annually, or $28,404 per 28-day pack.
This pricing, while substantial, is typical for advanced therapies in the rare disease space and will be a crucial factor for payers and patients to consider. Investors will be closely watching market uptake and reimbursement dynamics for ALYFTREK as it launches.
02—Key points
Key Highlights
- FDA approval of ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for cystic fibrosis.
- ALYFTREK targets patients aged 6+ with specific CFTR gene mutations (including F508del).
- Approval date: December 19, 2024.
- Annual U.S. Wholesale Acquisition Cost (WAC) set at $370,269.
- Per 28-day pack cost established at $28,404.
- This filing is made under Regulation FD.
- The information is not deemed 'filed' for Section 18 liability purposes.
03—Questions
Frequently Asked Questions
What is ALYFTREK and what does it treat?
ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) is a newly approved medication by the FDA for the treatment of cystic fibrosis in individuals aged 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ALYFTREK.
What is the cost of ALYFTREK in the United States?
The wholesale acquisition cost (WAC) for ALYFTREK in the United States has been established at $370,269 on an annual basis. This translates to $28,404 per 28-day pack.
What is the significance of this FDA approval for Vertex Pharmaceuticals?
The FDA approval of ALYFTREK is a major development for Vertex Pharmaceuticals, expanding its portfolio of treatments for cystic fibrosis and potentially reaching a broader patient population with its latest generation CFTR modulator therapy. It reinforces the company's leadership in the CF space.
When was ALYFTREK approved by the FDA?
ALYFTREK was approved by the U.S. Food and Drug Administration on December 19, 2024.
04—Continue